Fresenius SE Pre-Tax Income 2016-2024 | FSNUY
Fresenius SE annual/quarterly pre-tax income history and growth rate from 2016 to 2024. Pre-tax income can be defined as company's earnings or loss before taxes on income have been accounted for.
- Fresenius SE pre-tax income for the quarter ending September 30, 2024 was $0.456B, a 70.44% increase year-over-year.
- Fresenius SE pre-tax income for the twelve months ending September 30, 2024 was $0.528B, a 71.89% decline year-over-year.
- Fresenius SE annual pre-tax income for 2023 was $0.774B, a 73.9% decline from 2022.
- Fresenius SE annual pre-tax income for 2022 was $2.965B, a 31.38% decline from 2021.
- Fresenius SE annual pre-tax income for 2021 was $4.321B, a 1.51% increase from 2020.
Fresenius SE Annual Pre-Tax Income
(Millions of US $) |
| 2023 |
$774 |
| 2022 |
$2,965 |
| 2021 |
$4,321 |
| 2020 |
$4,256 |
| 2019 |
$4,381 |
| 2018 |
$5,508 |
| 2017 |
$4,451 |
| 2016 |
$4,144 |
| 2015 |
$3,622 |
Fresenius SE Quarterly Pre-Tax Income
(Millions of US $) |
| 2024-09-30 |
$456 |
| 2024-06-30 |
$170 |
| 2024-03-31 |
$449 |
| 2023-12-31 |
$-548 |
| 2023-09-30 |
$268 |
| 2023-06-30 |
$391 |
| 2023-03-31 |
$662 |
| 2022-12-31 |
$558 |
| 2022-09-30 |
$751 |
| 2022-06-30 |
$776 |
| 2022-03-31 |
$880 |
| 2021-12-31 |
$1,149 |
| 2021-09-30 |
$1,040 |
| 2021-06-30 |
$1,084 |
| 2021-03-31 |
$1,048 |
| 2020-12-31 |
$1,042 |
| 2020-09-30 |
$1,121 |
| 2020-06-30 |
$1,053 |
| 2020-03-31 |
$1,040 |
| 2019-12-31 |
$1,204 |
| 2019-09-30 |
$1,064 |
| 2019-06-30 |
$1,055 |
| 2019-03-31 |
$1,057 |
| 2018-12-31 |
$1,243 |
| 2018-09-30 |
$1,043 |
| 2018-06-30 |
$2,132 |
| 2018-03-31 |
$1,090 |
| 2017-12-31 |
$1,110 |
| 2017-09-30 |
$1,118 |
| 2017-06-30 |
$1,094 |
| 2017-03-31 |
$1,129 |
| 2016-12-31 |
$1,184 |
| 2016-09-30 |
$1,040 |
| 2016-06-30 |
$1,030 |
| 2016-03-31 |
$890 |
| 2015-12-31 |
$7,951 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Outpatient & Home Care |
$20.877B |
$24.011B |
|
Fresenius SE & Co is a health care company. It offers products and services for dialysis, hospitals and outpatient treatment. The company's business segment consists of Fresenius Medical Care is engaged in treating with chronic kidney failure; Fresenius Helios is a hospital operator; Fresenius Kabi supplies essential drugs, clinical nutrition products, medical devices and services and Fresenius Vamed plans, develops and manages healthcare facilities. Fresenius SE & Co is headquartered in Bad Homburg, Germany.
|
